Lysogene SAS (LYS):製薬・医療:M&Aディール及び事業提携情報

GlobalDataが発行した調査報告書(DATA904C8233)
◆英語タイトル:Lysogene SAS (LYS) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA904C8233
◆発行会社(リサーチ会社):GlobalData
◆発行日:2018年10月
◆ページ数:48
◆レポート形式:英語 / PDF
◆納品方法:Eメール
◆調査対象地域:フランス
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD250 ⇒換算¥27,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥54,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥81,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送いたしますので、請求書発行日より2ヶ月以内に銀行振込にて支払をお願いします。
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規代理店です。同社発行の市場リサーチレポート及びリサーチサービスに関するお問い合わせは弊社までお願い致します。GlobalData社の概要及び新刊レポートはこちらでご確認いただけます。

【レポートの概要】

Summary
Lysogene SAS (Lysogene) is a clinical research center that offers basic research and clinical development programs. The center offers clinical development of gene therapy for neurodegenerative disorders such as Parkinson and Alzheimer diseases. It also develops models in gene therapy trials for rare pediatric diseases. Lysogene holds expertise in pre-clinical efficacy, gene therapy, toxicology and bio-distribution studies in small and large animal models. The center also develops models and standards to find novel solutions in setting up gene therapy trials for rare pediatric diseases. It has partnership with academic institutions for its research activities. Lysogene is headquartered in Paris, France.

Lysogene SAS (LYS) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
Lysogene SAS, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Lysogene SAS, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Lysogene SAS, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Lysogene SAS, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
Lysogene SAS, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
Lysogene SAS, Pharmaceuticals & Healthcare, Deal Details 11
Venture Financing 11
Lysogene Raises USD22.6 Million in Series A Financing 11
Partnerships 12
Lysogene Enters into Agreement with Institute of Genetics and Molecular and Cellular Biology (IGBMC) and SATT Conectus 12
Alcyone Lifesciences Enters into Agreement with Lysogene 13
Lysogene Enters into Agreement with University of Massachusetts Medical School and Auburn University 14
Licensing Agreements 15
Sarepta Therapeutics Enters into License Agreement with Lysogene 15
ReGenX Biosciences Enters Into Licensing Agreement With Lysogene 16
Equity Offering 17
Lysogene Raises USD24.3 Million in IPO 17
Lysogene SAS – Key Competitors 18
Lysogene SAS – Key Employees 19
Lysogene SAS – Locations And Subsidiaries 20
Head Office 20
Recent Developments 21
Financial Announcements 21
Apr 16, 2018: Lysogene Reports First Quarter Financial Results and Provides Business Update 21
Mar 26, 2018: Lysogene: 2017 annual results 22
Jan 15, 2018: Lysogene Reports Fourth Quarter 2017 Financial Information 24
Oct 16, 2017: Lysogene: Financial Information for the Third Quarter of 2017 25
Sep 19, 2017: Lysogene Announces First Half 2017 Financial Results and Business Update 26
Jul 12, 2017: Lysogene: Financial Information for the Second Quarter of 2017 28
Apr 21, 2017: Lysogene: 2016 annual results 29
Apr 12, 2017: Lysogene: financial information for the 1st quarter of 2017 30
Corporate Communications 31
Sep 13, 2018: Lysogene announces changes in the composition of its Board of Directors 31
May 15, 2018: Lysogene Nominates Dr Ralph Laufer As Chief Scientific Officer And Member Of Executive Team 32
Apr 23, 2018: Lysogene Strengthens Board of Directors with Appointment of Dr. Peter Lichtlen 33
Sep 12, 2017: Lysogene Launches World Class Clinical Advisory Board 34
May 16, 2017: Lysogene Reinforces Its Management Team With the Nomination of Philippe Mendels-flandre as Chief Operating Officer 35
Product News 36
10/05/2017: Lysogene to Host Key Opinion Leader Meeting on Gene Therapy for Patients with Sanfilippo Syndrome Type A in New York City 36
Sep 21, 2017: Lysogene Holds First Parent Advisory Board in MPS IIIA 37
08/01/2018: Lysogene announces upcoming presentations at the 2018 international MPS symposium 38
03/28/2017: Lysogene Announces Baseline Data From First International Pivotal Observational Study In MPS IIIA 39
02/01/2018: Lysogene to Present Five Year Clinical Data in MPS IIIA at the 14th Annual WORLDSymposium 40
Product Approvals 41
Feb 06, 2018: Lysogene gets PIP Green Light from European Medicines Agency on MPS IIIA Pivotal Study; Paving Way for Clinical Trial Application Approvals 41
Feb 21, 2017: Lysogene Receives Orphan Drug Designation from EMA for LYS-GM101 for Treatment of GM1 Gangliosidosis 42
Feb 02, 2017: Lysogene Receives Orphan Drug Designation from FDA for LYS-GM101 for treatment of GM1 Gangliosidosis 43
Jan 18, 2017: Lysogene Receives Rare Pediatric Disease Designation from FDA for LYS-GM101 for Treatment of GM1 Gangliosidosis 44
Clinical Trials 45
May 30, 2017: Lysogene Completes Enrollment in First International Pivotal Observational Study in MPS IIIA 45
Other Significant Developments 46
Jul 23, 2018: Lysogene reports second quarter cash position and provides business and strategic update 46
Feb 14, 2018: The Alliance for Regenerative Medicine Announces Initial Slate of Presenting Companies at the Sixth Annual Cell & Gene Therapy Investor Day 47
Appendix 48
Methodology 48
About GlobalData 48
Contact Us 48
Disclaimer 48

List of Tables
Lysogene SAS, Pharmaceuticals & Healthcare, Key Facts, 2017 2
Lysogene SAS, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Lysogene SAS, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Lysogene SAS, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Lysogene SAS, Deals By Therapy Area, 2012 to YTD 2018 9
Lysogene SAS, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
Lysogene Raises USD22.6 Million in Series A Financing 11
Lysogene Enters into Agreement with Institute of Genetics and Molecular and Cellular Biology (IGBMC) and SATT Conectus 12
Alcyone Lifesciences Enters into Agreement with Lysogene 13
Lysogene Enters into Agreement with University of Massachusetts Medical School and Auburn University 14
Sarepta Therapeutics Enters into License Agreement with Lysogene 15
ReGenX Biosciences Enters Into Licensing Agreement With Lysogene 16
Lysogene Raises USD24.3 Million in IPO 17
Lysogene SAS, Key Competitors 18
Lysogene SAS, Key Employees 19

List of Figures
Lysogene SAS, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Lysogene SAS, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Lysogene SAS, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Lysogene SAS, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Lysogene SAS, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Lysogene SAS, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7
Lysogene SAS, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Lysogene SAS, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9

【免責事項】
http://www.globalresearch.jp/disclaimer

★リサーチレポート[ Lysogene SAS (LYS):製薬・医療:M&Aディール及び事業提携情報(Lysogene SAS (LYS) - Pharmaceuticals & Healthcare - Deals and Alliances Profile)]についてメールでお問い合わせはこちらでお願いします。

◆H&Iグローバルリサーチのお客様(例)◆